119 related articles for article (PubMed ID: 7040819)
1. Comparison of the techniques used for monitoring humoral immunity in cancer patients.
Renk CM; Gupta RK; Irie RF; Morton DL
J Surg Oncol; 1982 Mar; 19(3):155-61. PubMed ID: 7040819
[TBL] [Abstract][Full Text] [Related]
2. Humoral response of melanoma patients to two different tumor-associated antigens.
Chee DO; Gupta RK; Morton DL
J Surg Oncol; 1983 Aug; 23(4):228-35. PubMed ID: 6876798
[TBL] [Abstract][Full Text] [Related]
3. Serological detection of common human melanoma membrane antigens by microcomplement fixation and immunofluorescence.
Leong SP; Cooperband SR; Deckers PJ; Sutherland CM; Fried RM; Krementz ET
Oncology; 1983; 40(2):95-101. PubMed ID: 6338430
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response.
Ahn SS; Irie RF; Weisenburger TH; Jones PC; Juillard G; Roe DJ; Morton DL
Surgery; 1982 Aug; 92(2):362-7. PubMed ID: 7101129
[TBL] [Abstract][Full Text] [Related]
5. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
Mavligit G; Gutterman JU; McBride C; Hersh EM
Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
[No Abstract] [Full Text] [Related]
6. Antibodies and antigen expression in human melanoma detected by the immune adherence test.
Cornain S; de Vries JE; Collard J; Vennegoor C; van Wingerden I; Rümke P
Int J Cancer; 1975 Dec; 16(6):981-97. PubMed ID: 1104492
[TBL] [Abstract][Full Text] [Related]
7. A serologic study of cultured breast cancer cell lines: lack of antibody response to tumour specific membrane antigens in patients.
Higuchi M; Robinson DS; Cailleau R; Irie RF; Morton DL
Clin Exp Immunol; 1980 Jan; 39(1):90-6. PubMed ID: 7389200
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
Zörnig I; Halama N; Lorenzo Bermejo J; Ziegelmeier C; Dickes E; Migdoll A; Kaiser I; Waterboer T; Pawlita M; Grabe N; Ugurel S; Schadendorf D; Falk C; Eichmüller SB; Jäger D
Int J Cancer; 2015 Jan; 136(1):138-51. PubMed ID: 24839182
[TBL] [Abstract][Full Text] [Related]
9. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ
Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966
[TBL] [Abstract][Full Text] [Related]
10. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine.
Euhus DM; Gupta RK; Morton DL
Cancer Immunol Immunother; 1989; 29(4):247-54. PubMed ID: 2752392
[TBL] [Abstract][Full Text] [Related]
11. Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients.
Saxton RE; Irie RF; Ferrone S; Pellegrino MA; Morton DL
Int J Cancer; 1978 Mar; 21(3):299-306. PubMed ID: 204583
[TBL] [Abstract][Full Text] [Related]
12. Cellular and humoral immunity against human malignant melanoma.
Fossati G; Colnaghi MI; Porta GD; Cascinelli N; Veronesi U
Int J Cancer; 1971 Sep; 8(2):344-50. PubMed ID: 4943925
[No Abstract] [Full Text] [Related]
13. Immune response to autologous human melanoma: implication of class I and II MHC products.
Fossati G; Anichini A; Taramelli D; Balsari A; Gambacorti-Passerini C; Kirkwood JM; Parmiani G
Biochim Biophys Acta; 1986 Dec; 865(3):235-51. PubMed ID: 3539196
[No Abstract] [Full Text] [Related]
14. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019
[TBL] [Abstract][Full Text] [Related]
15. Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts.
Chen ZJ; Yang H; Ferrone S
J Immunol; 1991 Aug; 147(3):1082-90. PubMed ID: 1861071
[TBL] [Abstract][Full Text] [Related]
16. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
Jäger E; Nagata Y; Gnjatic S; Wada H; Stockert E; Karbach J; Dunbar PR; Lee SY; Jungbluth A; Jäger D; Arand M; Ritter G; Cerundolo V; Dupont B; Chen YT; Old LJ; Knuth A
Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4760-5. PubMed ID: 10781081
[TBL] [Abstract][Full Text] [Related]
17. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
Hsueh EC; Gupta RK; Qi K; Morton DL
J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558
[TBL] [Abstract][Full Text] [Related]
18. [How do melanoma cells circumvent the immune response? Consequences for future therapy attempts and current biopsy processing].
Dummer R; Böni R
Schweiz Med Wochenschr; 1995 Sep; 125(35):1638-41. PubMed ID: 7481617
[TBL] [Abstract][Full Text] [Related]
19. Humoral and cellular immune reactions 'in vitro' against allogeneic and autologous human melanoma cells.
Peter HH; Kalden JR; Seeland P; Diehl V; Eckert G
Clin Exp Immunol; 1975 May; 20(2):193-207. PubMed ID: 765012
[TBL] [Abstract][Full Text] [Related]
20. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
Lee Y; Bigner DD
Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
